BioNotebook: Two key fires at Retrophin, NewLink; three deals and three financings
This article was originally published in Scrip
Executive Summary
Boards of directors fire Retrophin CEO Shkreli, NewLink CFO Gordon Link; Rockwell, Baxter sign commercial deal; MacroGenics, Takeda enter second alliance; Sagent buys Omega; Portola, Titan price offerings; and Ignyta secures new debt.
You may also be interested in...
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front
Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.